knowledge -WSS

knowledge

author：focus 2025-10-01 10:38:24 - browse：19

Boxes of Wegovy — pharma coverage from STAT — Carsten Snejbjerg/Bloomberg

LONDON — The investment arm of Novo Nordisk’s parent foundation is buying drug manufacturer Catalent in a $16.5 billion deal, an acquisition that will give Novo additional sites as it builds up production of its booming obesity and diabetes drugs.

Under the deal, Novo Holdings is purchasing Catalent, a major contract development and manufacturing company with more than 50 sites globally. In turn, Novo Nordisk is buying three of Catalent’s fill-finish sites from the investment group for $11 billion. Novo Holdings manages the assets of the Novo Nordisk Foundation, which has a controlling stake in the pharmaceutical company.

Catalent has been involved in the production of Novo’s obesity treatment Wegovy. With the agreement, Novo will pick up sites that focus on filling drugs in Italy, Brussels, and Bloomington, Ind. All have already been doing work for Novo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： In new study, freeze

WSS

Study: People of West African ancestry at greater risk of cardiac amyloidosis

Sanofi strikes deal with Novavax, boosting the vaccine maker

First recipient of genetically engineered pig kidney has died

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

Readout LOUD podcast: brain research, obesity drug sales, Novartis

In new study, freeze

hotspot

knowledge

knowledge

Novavax promises a turnaround & Lilly roils the obesity market

Researchers on aging grapple with how to calculate biological age

Hepatitis C has a cure — but many Americans still lack access to it

Organ transplantation is at a crossroads. Major reform is needed

Jerome Adams on the need for new antivirals for Covid

How to improve immunocompromised access to mAb treatments

Drug repurposing or repositioning? The language matters

Software glitch causes Tandem insulin pump to shutdown, FDA warns

The cancer drug shortage isn’t new — and neither are the solutions

7 of the most gruesome medical devices in history

leisure time

FDA official pushes for dedicated emerging pathogens team

Russian special forces kill a gunman who broke into a private house near Moscow

What nurses really want: sufficient staffing for patient care

In new study, freeze

In new study, freeze

H5N1 bird flu: what we're starting to learn about infection in cows

hotspot

focus

hotspot

Wikipedia